Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00428766 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer
A Phase 1 study, sponsored by Morphotek.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00428766 is a Phase 1 study that has completed, run by Morphotek. The registered enrollment target is 24 participants.
The verdict
NCT00428766, a Phase 1 study, has completed, sponsored by Morphotek.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to establish the safest dose of MORAb-003 in subjects with advanced ovarian cancer. MORAb-003 is an antibody directed to an antigen on the surface of ovarian cancer cells.
Interventions
- DRUG MORAb-003
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2005-06 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00428766
The ClinicalTrials.gov registry entry for NCT00428766 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Morphotek, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MORAb-003 is the first listed.
NCT00428766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00428766 about?
NCT00428766 is a clinical study titled "Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer". The purpose of this study is to establish the safest dose of MORAb-003 in subjects with advanced ovarian cancer. MORAb-003 is an antibody directed to an antigen on the surface of ovarian cancer cells.
What is the current status of trial NCT00428766?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2005-06. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00428766?
The interventions under investigation include: MORAb-003 (DRUG).
Who is sponsoring clinical trial NCT00428766?
This trial is sponsored by Morphotek, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.